Latest filingSep 02, 2026Most recent Form 4
ADPT
Adaptive Biotechnologies Corp
NasdaqHealthcareBiological Products, (No Diagnostic Substances)
Insider activity for last month from 08/04 to 09/04. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$00 buys
Total selling$1.90B10 sells
Net open-market-$1.90B4 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period19transactions
- S · Open-market sells · dominant10 · 53%
- M · Option exercise8 · 42%
- G · Gifts1 · 5%
Activity by reported role
A joint filing can contribute to multiple roles19transactions
- Director · dominant11 · 58%
- CHAIR8 · 42%
Distinct insiders active
Reporting-owner CIKs by month · peak Aug 2026 (4)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeRobins Chad MCommon Stock · Direct
2,180,518Aug 18, 2026
Neupert Peter MCommon Stock · Direct
200,315Aug 17, 2026
Hershberg RobertCommon Stock · Direct
77,347Aug 18, 2026
Robins Chad MStock Option (right to buy) · Direct
0Aug 18, 2026
Owen Katey EinterzCommon Stock · Direct
66,100Aug 31, 2026
Neupert Peter MStock Option (right to buy) · Direct
0Aug 17, 2026
Hershberg RobertStock Option (right to buy) · Direct
0Aug 18, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 04 → Sep 04
LessMore
Top insiders
By absolute net value across the selected period- RM-$14.9M
- NM-$3.1M
- HR-$748.2k
Filing detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
ADPT transaction history
Filters apply within this company and selected period by default| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| ADPT | HERSHBERG ROBERT | DIR | sale | 15.6k | -$38.2M | S | −4.3% | 08/20 | 08/18 | |
| ADPT | HERSHBERG ROBERT | DIR | sale | 15.0k | -$36.5M | S | −4.3% | 08/20 | 08/18 | |
| ADPT | ROBINS CHAD M | CHAIR | sale | 204 | -$512k | S | −4.3% | 08/20 | 08/18 | |
| ADPT | ROBINS CHAD M | CHAIR | sale | 278k | -$681M | S | −4.3% | 08/20 | 08/18 | |
| ADPT | ROBINS CHAD M | CHAIR | sale | 2.52k | -$6.45M | S | −4.3% | 08/20 | 08/17 | |
| ADPT | ROBINS CHAD M | CHAIR | sale | 318k | -$799M | S | −4.3% | 08/20 | 08/17 | |
| ADPT | NEUPERT PETER M | DIR | sale | 69.6k | -$175M | S | −4.3% | 08/20 | 08/17 | |
| ADPT | NEUPERT PETER M | DIR | sale | 40.0k | -$100M | S | −4.3% | 08/20 | 08/17 | |
| ADPT | NEUPERT PETER M | DIR | sale | 15.0k | -$37.8M | S | −4.3% | 08/20 | 08/17 |
Adaptive Biotechnologies Corp Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Adaptive Biotechnologies Corp?
OWEN KATEY EINTERZ, HERSHBERG ROBERT, ROBINS CHAD M, NEUPERT PETER M.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Owen Katey Einterz reported a sale on Aug 26, 2026 valued at $24.9M. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $19,016,214.93. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.